// App-Quantinova.ai

3426 : A synthetic lethality approach to eradicate AML via synergistic activation of pro-apoptotic p53 by MDM2 and BET inhibitors

Researchers

Presenter

  • Sha Li

Principal Investigators

  • Anne Latif

  • Ashley Newcombe

  • Kathryn Gilroy

  • Neil Robertson

  • Xue Lei

  • Darren Finlay

  • Helen Stewart

  • Karina Barbosa

  • Brian Higgins

  • Tim Chevassut

  • Xu Huang

  • Mhairi Copland

  • Karen Keeshan

  • Ani Deshpande

  • Peter Adams

Medical Centers

  • Sanford Burnham Prebys Medical Discovery Institute, Heidelberg, CA

  • University of Glasgow, Glasgow, United Kingdom

  • University of Sussex, London, United Kingdom

  • Roche Innovation Center, New York, NY

Locations

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute myelocytic leukemia

Biomarkers

  • Mouse double minute 2 homolog

  • B-cell lymphoma 2

  • Cyclin-dependent kinase 4

  • Tumor protein p53

Drug/Treatment

  • TP53

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved